Nobody puts cancer in a corner!

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 10
Volume 17
Issue 10

Enticing monetary donations out of homeowners in exchange for address labels remains a staple in philanthropic fundraising. But the Stand Up To Cancer (SU2C) organization has taken a more modern approach to recruiting support through online social networking.

Enticing monetary donations out of homeowners in exchange for address labels remains a staple in philanthropic fundraising. But the Stand Up To Cancer (SU2C) organization has taken a more modern approach to recruiting support through online social networking. Their “Virtual Stand Up” invites users to join the group’s FaceBook page, create a YouTube video, or send a real-time, short message called a “tweet.” A $1 donation nets a personalized “star” in SU2C’s virtual constellation.

Articles in this issue
Nanoparticles extend survival in pancreatic ca patients
Nobody puts cancer in a corner!
ACS spends big money to highlight healthcare system deficiencies
Visits to oncologists up, but profit per patient is on the decline
Report finds high rate of adoption of IMRT
Some HER2+ tumors prove resistant to trastuzumab
NIH bankrolls molecular probes for targeted therapy
Oropharyngeal ca: IMRT spares salivary glands
Fear of audit, lazy billing erodes profits
Apoptosis inducer hits melanoma with double whammy
Triathlon for an MPD cure
Oncology electronic health records: More than just an e-secretary
Barrie Cassileth, an integrative medicine pioneer
Move to make CME an out-of-pocket cost gains ground
Is concurrent chemotherapy/IMRT too toxic and dangerous for use in H&N cancer?
Recent Videos
3 experts in this video
Sequencing Treatment for Endocrine-Resistant Disease
3 experts in this video
Treatment Options for Metastatic Breast Cancer
3 experts in this video
Treatment of Locally Advanced Disease
3 experts in this video
Overview of HR+ Breast Cancer Treatment
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Enfortumab Vedotin Combo Supersedes Other Advanced Bladder Cancer Options
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
Incentivizing RCC Research Investment Across Lower-Income Countries
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
EV-302 Trial Shows ‘Impressive’ Data in Bladder Cancer Responder Population
According to Megan Mullins, PhD, MPH, challenging cultural norms surrounding death and dying may reduce the receipt of low-value end-of-life cancer care.
Addressing Social Norms Influencing Receipt of Aggressive End-of-Life Care
Identifying and Managing Toxicities From Pembrolizumab Combinations
Identifying and Managing Toxicities From Pembrolizumab Combinations
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Managing AEs Associated With The EV-302 Trial Regimen in Bladder Cancer
Related Content
Sitravatinib Cannot Be Safely Combined With Nivolumab/Ipilimumab in RCC

Sitravatinib Cannot Be Safely Combined With Nivolumab/Ipilimumab in RCC

Tim Cortese
February 24th 2025
Article

A phase 1/1b trial found that the triplet combination elicited an ORR of 45.5% and a median PFS of 14.5 months in previously untreated clear cell RCC.

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Pioneering Progress in Gynecologic Oncology: A Career of Many Advancements

Pioneering Progress in Gynecologic Oncology: A Career of Many Advancements

Ariana Pelosci
February 24th 2025
Article

As a gynecologic oncology surgeon, Mario M. Leitao, MD, FACOG, FACS, highlights how his career has evolved through using robotic surgery, new fertility preservation techniques, and his contributions to the research field.

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Highlighting Insights From the Marginal Zone Lymphoma Workshop

Thomas Habermann, MD;Julie M. Vose, MD, MBA;James R. Cerhan, MD, PhD;Alexandar Tzankov, MD;Andrew D. Zelenetz, MD, PhD
February 17th 2025
Podcast

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Rucaparib Findings Highlight Need for More Data in BRCA+ Ovarian Carcinoma

Rucaparib Findings Highlight Need for More Data in BRCA+ Ovarian Carcinoma

Tim Cortese
February 23rd 2025
Article

Data show that rucaparib yielded a median OS of 19.4 months compared with 25.4 months with chemotherapy in relapsed BRCA-mutated ovarian carcinoma.

Developments in CAR T-Cell and Bispecific Therapies in R/R Multiple Myeloma

Developments in CAR T-Cell and Bispecific Therapies in R/R Multiple Myeloma

ONCOLOGY Staff
February 22nd 2025
Article

Hematology oncology experts discuss recent developments in CAR T-cell therapies as well as bispecific therapies for the treatment of patients with R/R MM.